4//SEC Filing
Turtle Cameron 4
Accession 0000899243-21-003649
CIK 0001731831other
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 7:15 PM ET
Size
11.2 KB
Accession
0000899243-21-003649
Insider Transaction Report
Form 4
Turtle Cameron
Chief Business Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−9,469→ 0 totalExercise: $17.00Exp: 2028-06-20→ Common Stock (9,469 underlying) - Disposition from Tender
Common Stock
2021-01-26−50,699→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−53,157→ 0 totalExercise: $13.20Exp: 2028-11-05→ Common Stock (53,157 underlying)
Footnotes (4)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
- [F2]Includes 78 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.
- [F3]The option vests over four years after June 18, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
- [F4]The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Documents
Issuer
Eidos Therapeutics, Inc.
CIK 0001731831
Entity typeother
Related Parties
1- filerCIK 0001758363
Filing Metadata
- Form type
- 4
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 7:15 PM ET
- Size
- 11.2 KB